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The first-line treatment for children presenting with idiopathic nephrotic syndrome (NS) is oral corticosteroids. Although the majority of children respond to steroids, 
80% of children experience a relapsing course and among these 
half relapse while on reducing doses of corticosteroids or within 
2 weeks of completion of steroid therapy (steroid-dependent 
NS [SDNS]) [1]. These children with SDNS need long-term 
steroid usage to maintain sustained remission and hence are at 
risk of steroid toxicity such as hypertension, obesity, cataracts, 
psychosis, striae, and growth failure [2,3]. In addition, relapses 
may continue into adulthood. Hence, SDNS is not regarded 
as a benign condition, even though the renal function is not 
compromised [4,5].
Cyclophosphamide (Cyp) is a well-known alternative agent to 
spare the use of steroids and avoid the side effects that result from 
the long-term steroid therapy. Use of Cyp typically reduces the 
risk of relapse in comparison with prednisolone by about 50% for 
1 year during and after the treatment. Many studies have shown 
that treatment with Cyp reduces the risk of relapse at 6, 12, and 24 
months when compared to placebo or prednisolone alone [6-10]. 
Cyp may be given orally or as monthly pulse intravenous 
(IV) therapy. However, there is no consensus on the route of 
administration of Cyp in children with SDNS. The potential 
advantages of monthly IV therapy include better compliance, 
avoidance of frequent blood sampling to monitor lymphopenia 
which may be a challenge in younger children and use of lesser 
cumulative dose as compared to oral Cyp which may result in 
lesser toxicity.
The cumulative dose is higher in the oral group when compared 
to the IV group. Infections are significantly more common in 
children treated with oral Cyp compared with IV therapy. The 
other side effects seen with IV Cyp are bone marrow suppression, 
alopecia, hemorrhagic cystitis, and vomiting [11]. There are very 
few studies that reported the utility of IV pulse Cyp in SDNS. 
Hence, this study was undertaken to determine the efficacy and 
safety of IV Cyp in children with SDNS.
MATERIALS AND METHODS
This was a retrospective single-center study undertaken in a large 
government hospital in South India. The data were retrieved from 
the records of children attending the pediatric nephrology clinic 
between 2005 and 2016. Children with SDNS who received the 
complete schedule of IV Cyp were included in the study. Children 
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who received other alternate drugs such as calcineurin inhibitors 
or mycophenolate mofetil (MMF) before receiving IV Cyp were 
excluded. Age at onset of disease, clinical characteristics of initial 
episode of NS, renal histology if available, number of relapses, 
use of other immunosuppressive treatments (e.g., levamisole, 
long-term steroid treatment) were recorded. Treatment duration 
and cumulative dose of Cyp were calculated. Height and weight 
were recorded at diagnosis of NS, at start of Cyp, at first relapse 
after Cyp, and at last follow-up visit. IV Cyp therapy was given 
once a month for 6 months. Adequate hydration was ensured 
during and post-IV infusion. Cyp was started at dose of 500 mg/m2 
and increased to maximum dose of 750 mg/m2. Oral prednisolone 
1.5 mg/kg was given alternate day for 4 weeks, then tapered by 
0.25 mg/kg every month and subsequently stopped. Children 
were initially followed up monthly for the first 6 months and 
then quarterly. At each visit, they were monitored for proteinuria 
by dipstick and side effects of Cyp and prednisolone. The drug 
was withheld if total white cell count was <3000 cells/mm3 or if 
the platelet counts were <50000/mm3. Following treatment with 
IV Cyp and after prednisolone has been stopped, relapse of NS 
was treated with standard treatment guidelines, and the course 
of NS was followed up and labeled as infrequently relapsing 
NS (IFRNS) and frequently RNS (FRNS) according to standard 
definitions. Permission and ethical clearance have been obtained 
from the hospital ethical committee to publish the data.
Definitions Used in the Study
SDNS
SDNS is defined as 2 consecutive relapses, when on alternate 
day steroids or within 14 days of its discontinuation. Relapse 
was defined as urine albumin 3+ to 4+ or 2+ with edema was 
considered as relapse. Remission was defined as urine albumin 
nil or traces for 3 consecutive days [12]. A sustained remission 
was defined as a relapse-free period for 6 months or more. In 
addition, in those whose steroid response category was changed 
to infrequently relapsing or frequently relapsing were considered 
as responders. Those children who continued to be dependent on 
prednisolone were considered as non-responders.
Statistical analysis was done using Epi Info™ for Windows 
software. The mean relapse rates (RR) and prednisolone dose 
(PD) before and after Cyp were calculated using paired t-test. 
RESULTS
Fifty patients with SDNS were treated with IV Cyp, seven patients 
did not complete the treatment and were excluded from the 
analysis. Baseline characteristics of patients are shown in Table 1. 
The median period of follow-up in these children was 4 years 
(interquartile range [IQR] = 2.1- 5.5 years), the maximum follow 
period being 11 years with the maximum period of remission 
being 8 years. The median age of children in our study at the time 
of last follow-up was 11 years with IQR of 7.2–14.5 years.
Only two patients had kidney biopsy before starting treatment 
with IV Cyp, the indication being the presence of atypical 
features, one had minimal change NS (MCNS) and other patient 
had mesangioproliferative NS. After treatment with IV Cyp, 
seven patients among the non-responders underwent biopsy 
before starting with tacrolimus, five had MCNS, one patient had 
focal segmental glomerulosclerosis (FSGS) and one had C1Q 
nephropathy. Overall, only the child with mesangioproliferative 
glomerulonephritis responded to IV Cyp and six children with 
MCNS and one each with FSGS and C1Q nephropathy did not 
respond.
The overall response to IV Cyp is shown in Table 2. 24 (56%) 
of the 43 patients stayed in remission throughout the course 
of Cyp treatment and prednisolone could be stopped and were 
considered as Cyp responsive. The remaining 19 (44%) children 
had relapsed while on Cyp therapy (Cyp resistant) and required 
treatment with alternate immunosuppressant. Nine were given 
a trial of levamisole, nine children were started on tacrolimus, 
out of which two patients later required MMF and rituximab, 
one patient was lost for follow-up. 19 of the 24 Cyp responsive 
patients were in remission 6 months after stopping Cyp treatment 
(Cyp sensitive) while the remaining five patients relapsed within 
6 months of stopping Cyp treatment (Cyp dependent). Of the 
24 children who responded, 9 children (20.9%) were relapse-
free till the time of last follow-up and the median follow-up in 
these children was 2.1 years (IQR of 0.95-2.9 years). The exact 
follow-up period in these nine children were 5 months, 10 months, 
1 year, 1 year 7 months, 2 years 2 months, 2 years 6 months, 
2 years 9 months, 3 years, and 5 years. 13 (30.23%) children out 
Table 1: Baseline characteristics in the study
Age at onset of NS (in years)
Male : Female
Duration of NS in years 
before starting therapy with 
cyclophosphamide
Age at initiation of 
cyclophosphamide therapy
(in yrs)
Cumulative dose of 
cyclophosphamide (mg/kg)
Number of patients treated 
with levamisole before 
cyclophosphamide
Median age 2.5yrs (IQR 1.5-6yrs)
22:21
Median age 3 yrs (IQR 1-5yrs)
Median age 6yrs (IQR 3-11yrs)
Median dose 150mg/kg  
(IQR 125-159mg/kg)
16 (37.2%)
Table 2 : Response to cyclophosphamide therapy
Cyp resistant
Cyp responsive
No relapse
IFRNS
FRNS
19 (44.1%)
24 (55.8%)
09 (20.9%)
13 (30.23%)
2 (4.6%)
Mean Relapse rate (RR per year) (In 
Cyp responsive patients)
Before cyclophosphamide
After cyclophosphamide
Mean Prednisolone dose (PD in mg/kg) 
(In Cyp resistant patients)
Before cyclophosphamide
After cyclophosphamide
3.10±2.21
0.99±2.02 P value ˂0.001
1.16±0.42
0.54±0.33 P value <0.001
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of 24 who responded were IFRNS and 2 (4.5%) children were 
FRNS. The mean RR was calculated for those children who 
responded and was 3.10 ± 2.21 and 0.99 ± 2.02 before and after 
treatment with Cyp, respectively, p ˂ 0.001. The mean PD for the 
non-responders with p ˂ 0.001 before and after treatment with 
Cyp was 1.16 ± 0.42 and 0.54 ± 0.33, respectively.
Side effects of Cyp were documented during Cyp therapy, none 
of the children in our study had hemorrhagic cystitis, 3 (6.9%) 
developed alopecia, 3 (6.9%) children had leukopenia, 4 (9.3%) 
children developed headache, and vomiting after the pulse 
doses of Cyp which subsided with simple supportive measures. 
6 (13.9%) had lower respiratory tract infection, 8 (18.6%) had 
upper respiratory tract infection (URTI), 2 (4.6%) had candidal 
skin infection, 1 (2.3%) each had acute gastroenteritis, measles, 
spontaneous bacterial peritonitis, and non-bullous impetigo. 
DISCUSSION
Cyp has been used in childhood NS since 1960s. Oral Cyp has 
been widely used and most of the studies have been on oral Cyp. 
In our study, we tried to evaluate the efficacy and side effects of IV 
Cyp in SDNS. The mean age of onset of NS in our study was 4.05 
± 3.3 years. Srivastava et al. in their study found that in majority 
of children with NS, the onset of disease occurs before the age of 5 
years [13]. The mean age of initiation of Cyp therapy was 7.4 ± 4.7 
years, whereas in the study by Prasad et al., it was similar being 7.6 
± 5 years. Our primary objective was to evaluate the efficacy of IV 
Cyp in SDNS in the form of change in steroid response category.
In our study, nine patients underwent renal biopsy as described 
in the results section and there was no correlation between 
response to IV Cyp and histopathology with only child with 
mesangioproliferative glomerulonephritis responding to therapy. 
In the study by Prasad et al., among the 14 children biopsied, nine 
had MCNS and five had FSGS. They have not mentioned about 
the correlation of histopathology and response [14].
In this study, 24 (55.8%) of the 43 children studied responded 
to IV Cyp, and steroids could be stopped, 19 (44.1%) continued 
to be on steroids and were labeled as Cyp resistant. Out of the 
24 children who responded (Cyp responsive), 9 (20.9%) of them 
were in remission and off steroids till their last follow-up (median 
follow-up 2.1 years, IQR of 0.95–2.9 years). Prasad et al. in their 
study compared IV with oral Cyp and found that IV Cyp was 
more effective than oral Cyp. In 26 children who received IV 
Cyp, 15 (57.7%) had sustained remission for 6 months.
5 (19.2%) were infrequent relapsers, 3 (11.5%) were frequent 
relapsers, and 3 (11.5%) continued to be steroid dependent [14]. 
The overall improved category in their study was 88.5% when 
compared to 55.1% in our study. This difference may be due to 
higher number in our study and also, it has been showed in a study 
that certain genetic polymorphisms of glutathione-S-transferase 
may predict a better response to IV pulse Cyp treatment and in the 
same study Sharda et al. also reported a benefit in 50% of patients 
after IV Cyp, but they presented no exact outcome data. 37 of the 
74 patients showed response, but this study included both steroid 
sensitive and steroid-resistant NS [15]. In a prospective study, 
by Bhagwani and Sharada 16 children with SDNS were treated 
with IV pulse Cyp and followed up for 2 years. After 2 years of 
follow-up, 9 children (56.25%) had sustained remission, 4 (26%) 
were infrequently relapsing, 1 (6.25%) was FRNS, and 2 (12.5%) 
continued to be SDNS [16]. In our study, 19 of the 43 children 
continued to be dependent on prednisolone and were labeled 
as CPA resistant and the dependent dose of prednisolone was 
significantly reduced after Cyp therapy. The median cumulative 
dose of Cyp was 150 mg/kg, compared to 100 mg/kg in the Prasad 
et al. study.
50 children included
7 did not complete
 therapy
43 included for
 analysis
24 CPA responsive
No relapse on therapy
19 were in remission  for
 6mths after stopping
 CPA therapy 
(CPA sensitive)
5 relapsed within 6 mths
 of stopping therapy
(CPA dependant)
19 CPA resistant
Had relapse on therapy
9 treated with levamisole 9 treated with 
tacrolimus
1 lost for 
follow up
Figure 1: Flow diagram of the study
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The side effects were documented and none of them had 
serious side effects requiring discontinuation of Cyp therapy. 
Therapy was deferred till they recovered from leucopenia or 
infections. In the study by Prasad et al., out of 26 children, two 
developed leucopenia, three had alopecia. One had pneumonia 
and two had nausea and vomiting which were comparable with 
our study except for the higher incidence of infection in our study, 
which may be partly related to the low socioeconomic status of the 
patients in our study. Furthermore, in their study, side effects were 
significantly more in children treated with oral Cyp. In the study 
by Bhagwani and Sharada, out of 16 patients, two had nausea and 
vomiting, one had alopecia, one had thrombocytopenia, five had 
mild URTI and one developed chickenpox. None of the children 
developed hemorrhagic cystitis.
Ours being a resource-poor country, cost and affordability 
also play an important role in the treatment of these children. 
When we compared the cost between IV Cyp, tacrolimus, and 
MMF, it was found that the cost of tacrolimus and MMF was 
about 30 and 60 times that of IV Cyp (considering a 30 kg child 
with a body surface area of 1 m2 , 6 doses of IV Cyp would 
cost about Rs. 1000, tacrolimus (0.1 mg/kg/day for 1 year) costs 
Rs. 30,000, and MMF (1000 mg/m2/day for 1 year) would cost 
around Rs. 60,000. These drugs sometimes have to be continued 
for 2–3 years that would further increase the cost proportionately 
and obviously cost will play an important role in the compliance 
to treatment.
The limitation of our study was that this was a retrospective 
study including patients treated over the last 10 years; hence, 
we did not have uniform follow-up period for all patients which 
would have provided better interpretation. Our sample size was 
small with only 43 patients in the study, and also comparison with 
oral Cyp would have given us better idea about the advantages of 
IV Cyp over oral Cyp.
CONCLUSIONS
Our study, there was fairly good response to IV Cyp with 55.8% 
response rate. About 21% of children did not have any relapse 
and 30% were infrequent relapsers, which are quite acceptable 
considering the low cost of Cyp which is about 30 and 60 times 
cheaper when compared to tacrolimus and MMF, respectively. 
Hence, although not an ideal option, IV Cyp can be tried as the 
initial alternative immunosuppressant in SDNS, particularly in 
the resource-poor countries.
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